SMART advances cancer therapy – Tumour Treating Fields (TTF) – with a novel microfluidic device

SMART innovation - 3D microfluidic device with embedded electrodes - enables the application of an electric field therapy to single or aggregated cancer cells in a 3D microenvironment.

Singapore – Cancer is prevalent in Singapore, with 37 people being diagnosed daily, according to the Singapore Cancer Society. The three known tools to fight cancer are: Surgery, radiation and chemotherapy. A novel treatment, known as Tumour Treating Fields (TTF), is gaining traction and is FDA-approved for Glioblastoma, a type of brain cancer. Pre-clinical trials are gathering pace for breast, cervical and colorectal cancers, amongst others.

Having worked on microfluidic devices (integrated, portable devices that provides a 3D microenvironment for cells, allowing laboratory tests to be done swiftly) since 2012, research scientists Dr Giulia Adriani and Dr Andrea Pavesi (a husband-and-wife team), at the Singapore-MIT Alliance for Research and Technology (SMART) [新加坡-麻省理工学院科研中] have engineered a novel 3D microfluidic culture platform for TTF application. This groundbreaking research was recently published in Nature Scientific Reports.

Read full news release at